Cervical cancer is the fourth most common cancer among women, after breast, colorectal, and lung cancer. 1 About 80% of new cases of cervical cancer occur in developing countries. 2 Oncogenic HPV infection is the major etiological agent of cervical cancer, of which 70% are caused by HPV-16 and HPV-18 type. 2,3 It may take up to 5-10 years for the infection to progress to the precancerous lesion. 3 HPV genotype distribution varies with the severity of the cervical disease, patient demographics such as age, as well as geographical location. 4,5 There has been a large decline in cervical cancer incidence and death rate in countries with regular cervical screening program during the past few decades. Unfortunately, there is no such decline in countries without such a screening program. The disproportionate burden of cervical cancer in developing countries with poor health systems is mainly due to a lack of effective screening program. 2 In developing countries, limited access to effective screening means that the disease is often not identified until it is further advanced and symptoms develop. In addition, prospects for the treatment of such late-stage disease may be poor, resulting in a higher rate of death from cervical cancer in these countries. 6 Background and objective: Cervical cancer is the fourth most common cancer among women. Carcinogenic Human Papilloma Virus (HPV) infection is the major etiological agent for cervical cancer, of which70% are caused by HPV-16 and HPV-18 genotype infection. This study aimed to detect high risk HPV (16,18) in women with different abnormalities in pap smear to allow subsequent more accurate management of the cases and provide information that assists in future development of guidelines in our hospital. Methods: We performed a cross-sectional study on 100 ladies with an abnormal pap smear. Subjects were interviewed and underwent cervical testing with broom using liquid based samples to confirm the cytological abnormality and test for HPV genotypes 16 and 18 using Polymerase Chain Reaction (PCR). Then, colposcopy referral was done according to local protocols. Results: The median age of the subjects was 34. The prevalence of HPV genotypes 16,18 in the whole studied sample was 36%. Various studied risk factors showed significant association with abnormal pap smear and positive HPV genotypes 16,18, including the number of partners, increasing parity, age at first pregnancy, and smoking. Data were analyzed by the statistical package for the social sciences (version 23). Conclusion: The prevalence of HPV 16,18 was 36% in the sample, with the highest proportion being among those with high-grade lesions. Those using natural methods of contraception had higher rates of infection in comparison with other methods.
Nausea and vomiting are very frequent complaints of pregnant women. Erroneously called "morning sickness" in 80% of these women, symptoms may continue throughout the day. Seventy-five percent of pregnant women express nausea and vomiting, lasting an average of 35 days. Half of them will report relief by 14 weeks and 90% by 22 weeks. 1,2 Women with severe nausea and excessive vomiting during pregnancy have hyperemesis gravidarum (HG) which occurs in approximately 0.3-2% of pregnancies. 3 Various HG definitions combine a number of symptoms that include protracted vomiting and nausea in pregnancy, accompanied by weight loss, disturbance of electrolyte balance, ketonuria, and dehydration or hospitalization; however, there are no unequivocal diagnostic criteria for HG as it is a diagnosis of exclusion. 4 Risk factors reported to be associated with NVP and hyperemesis are low maternal age, first parity, 5 female offspring, 6-8 multiple pregnancy, 7 hyperthyroidism, molar pregnancy, gastrointestinal disorders, Background and objective: Hyperemesis gravidarum can be defined as intractable nausea and vomiting, leading to electrolyte imbalance, ketonuria, nutrition deficiency, and weight loss during pregnancy. This study aimed to investigate the association of the platelet to lymphocyte ratio and plateletcrit with the presence of hyperemesis gravidarum. Methods: A case-control study was conducted at Maternity Teaching Hospital in Erbil city, Kurdistan region of Iraq, between January 1st, 2017 and January 1st, 2018. A convenience sample of 120 pregnant women, of which 60 of them with a diagnosis of hyperemesis gravidarum admitted to the emergency department, were regarded as cases. The other 60 visited the outpatient department with mild discomfort, but not having hyperemesis gravidarum were regarded as controls. Age, gestational age, gravida, parity, height, and weight and laboratory parameters, including complete blood count from which we had platelet to lymphocyte ratio and plateletcrit %, were recorded on a specially designed questionnaire. Chi-square test, Fisher's exact test, Student's t-test, Youden's index were used to determine the associations. Results: The platelet to lymphocyte ratio and plateletcrit were higher in the hyperemesis gravidarum groups than controls (P <0.001). The area under the curve for platelet to lymphocyte ratio and plateletcrit were 0.887 and 0.936, respectively, with P <0.001. Platelet to lymphocyte ratio >145.07 and plateletcrit >0.205% were significantly related to an increased risk of hyperemesis gravidarum. Conclusion: The platelet to lymphocyte ratio and plateletcrit are higher in hyperemesis gravidarum cases and may have a predictive value of the development of hyperemesis gravidarum as further studies needed in the future to confirm.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.